0.6552

0.34% 0.0022

Pre-market: .67 0.0148 +2.26%

Applied Therapeutics Inc (APLT)

Overview News Price History Option Chain Financials Discussions Forecast

Applied Therapeutics Inc stock is traded at $0.6552, with a volume of 7.39M. It is up +0.34% in the last 24 hours and down -25.55% over the past month. Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Previous Close:

$0.653

Open:

$0.6382

24h Volume:

7.39M

Relative Volume:

1.19

Market Cap:

$76.24M

Revenue:

Net Income/Loss:

$-119.76M

P/E Ratio:

-0.4853

EPS:

-1.35

Net Cash Flow:

$-55.17M

1W Performance:

+2.41%

1M Performance:

-25.55%

6M Performance:

-87.25%

1Y Performance:

-74.20%

1-Day Range:

$0.61

$0.75

1-Week Range:

$0.606

$0.75

52-Week Range:

$0.6016

$10.62

Applied Therapeutics Inc Stock (APLT) Company Profile

Name

Applied Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

212-220-9226

Address

545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY

Employee

Twitter

@Applied_Tx

Next Earnings Date

2024-11-07

Latest SEC Filings

APLT's Discussions on Twitter

Compare APLT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APLT Applied Therapeutics Inc	0.6552	76.24M	0	-119.76M	-55.17M	-1.35
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-23-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-02-24	Downgrade	UBS	Buy → Neutral
Nov-29-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-31-24	Initiated	William Blair	Outperform
Mar-26-24	Initiated	RBC Capital Mkts	Outperform
Feb-22-24	Initiated	Leerink Partners	Outperform
Jan-04-22	Downgrade	Barclays	Overweight → Equal Weight
Aug-27-21	Downgrade	Goldman	Neutral → Sell
Jun-25-21	Resumed	Goldman	Neutral
Oct-08-20	Initiated	Truist	Buy
Apr-22-20	Initiated	Goldman	Buy
Feb-27-20	Initiated	Barclays	Overweight
Jun-10-19	Initiated	Citigroup	Buy
Jun-10-19	Initiated	Cowen	Outperform
Jun-10-19	Initiated	Robert W. Baird	Outperform

View All

Applied Therapeutics Inc Stock (APLT) Latest News

03:34 AM

Hennion & Walsh Asset Management Inc. Raises Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

03:34 AM

02:25 AM

Applied Therapeutics, Inc. (NASDAQ:APLT) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

02:25 AM

Jan 21, 2025

APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire

Jan 21, 2025

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Jan 21, 2025

APLT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire

Jan 21, 2025

APLT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - GlobeNewswire Inc.

Jan 21, 2025

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Applied Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesAPLT - PR Newswire

Jan 21, 2025